CY1116575T1 - Χρησεις αρωματικου-κατιοντικου πεπτιδιου - Google Patents

Χρησεις αρωματικου-κατιοντικου πεπτιδιου

Info

Publication number
CY1116575T1
CY1116575T1 CY20151100675T CY151100675T CY1116575T1 CY 1116575 T1 CY1116575 T1 CY 1116575T1 CY 20151100675 T CY20151100675 T CY 20151100675T CY 151100675 T CY151100675 T CY 151100675T CY 1116575 T1 CY1116575 T1 CY 1116575T1
Authority
CY
Cyprus
Prior art keywords
aromatic
net positive
cationic peptide
minimum
relationship
Prior art date
Application number
CY20151100675T
Other languages
English (en)
Inventor
Hazel H Szeto
Kesheng Zhao
Peter W Schiller
Original Assignee
Cornell Research Foundation, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Research Foundation, Inc. filed Critical Cornell Research Foundation, Inc.
Publication of CY1116575T1 publication Critical patent/CY1116575T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)

Abstract

Η εφεύρεση παρέχει μέθοδο ελάττωσης ή πρόληψης της μετάπτωσης μιτοχονδριακής διαπερατότητας. Η μέθοδος περιλαμβάνει τη χορήγηση αποτελεσματικής ποσότητας αρωματικού-κατιοντικού πεπτιδίου που έχει ένα τουλάχιστον καθαρό θετικό φορτίο, ένα ελάχιστο 4 αμινοξέων, ένα μέγιστο περίπου 20 αμινοξέων, μια σχέση μεταξύ του ελάχιστου αριθμού καθαρών θετικών φορτία (pm) και του συνολικού αριθμού υπολειμμάτων αμινοξέων (r) όπου 3pm είναι ο μεγαλύτερος αριθμός ο οποίος είναι μικρότερος ή ίσος με r + 1, και a η σχέση μεταξύ του ελάχιστου αριθμού αρωματικών ομάδων (a) και του συνολικού αριθμού καθαρών θετικών φορτίων (pt) όπου 2a είναι ο μεγαλύτερος αριθμός ο οποίος είναι μικρότερος ή ίσος με pt + 1, εκτός όταν το a είναι 1, το pt μπορεί επίσης να είναι 1.
CY20151100675T 2003-02-04 2015-08-03 Χρησεις αρωματικου-κατιοντικου πεπτιδιου CY1116575T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44477703P 2003-02-04 2003-02-04
US53569004P 2004-01-08 2004-01-08
EP20130178043 EP2656854B1 (en) 2003-02-04 2004-02-03 Uses of aromatic-cationic peptide

Publications (1)

Publication Number Publication Date
CY1116575T1 true CY1116575T1 (el) 2017-03-15

Family

ID=32853391

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20141100064T CY1114959T1 (el) 2003-02-04 2014-01-24 Μεθοδοι προληψης της μεταπτωσης μιτοχονδριακης διαπερατοτητας
CY20151100675T CY1116575T1 (el) 2003-02-04 2015-08-03 Χρησεις αρωματικου-κατιοντικου πεπτιδιου

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20141100064T CY1114959T1 (el) 2003-02-04 2014-01-24 Μεθοδοι προληψης της μεταπτωσης μιτοχονδριακης διαπερατοτητας

Country Status (14)

Country Link
US (8) US7576061B2 (el)
EP (9) EP3659618A1 (el)
JP (7) JP4838114B2 (el)
CN (3) CN102784383B (el)
AU (1) AU2004209663B2 (el)
CA (1) CA2515080C (el)
CY (2) CY1114959T1 (el)
DK (3) DK2865385T3 (el)
ES (3) ES2540897T3 (el)
HK (6) HK1131995A1 (el)
HU (1) HUE027110T2 (el)
PT (2) PT1599216E (el)
SI (1) SI2656854T1 (el)
WO (1) WO2004070054A2 (el)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3659618A1 (en) 2003-02-04 2020-06-03 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
PT2604285E (pt) * 2003-05-01 2014-11-12 Cornell Res Foundation Inc Método e complexos transportadores para entregar moléculas às células
CA2971928C (en) * 2004-01-23 2019-01-08 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
EP3725324A1 (en) * 2005-09-16 2020-10-21 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing cd36 expression
AU2014203126B2 (en) * 2005-09-16 2016-03-10 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
ES2458870T3 (es) 2008-02-07 2014-05-07 Cornell University Procedimientos para prevenir o tratar la resistencia a la insulina
DK2262520T3 (en) 2008-02-26 2017-08-07 Univ Cornell COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury
DE102008061044A1 (de) 2008-12-11 2010-06-17 Henkel Ag & Co. Kgaa Zusammensetzung mit antioxidativ wirksamen Peptiden
EP3199173B1 (en) * 2009-03-20 2019-04-24 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention and treatment of burn injuries
US20110039766A1 (en) * 2009-08-12 2011-02-17 Szeto Hazel H Methods for preventing or treating metabolic syndrome
DK2470191T3 (da) 2009-08-24 2014-07-07 Stealth Peptides Int Inc Fremgangsmåder og præparater til forebyggelse eller behandling af oftalmiske tilstande
CN102711785A (zh) * 2009-10-05 2012-10-03 康奈尔大学 预防或治疗心力衰竭的方法
EP2519249A4 (en) * 2009-12-31 2013-06-26 Stealth Peptides Int Inc METHODS OF REALIZING AORTO-CORONARY BRIDGE
US20130195837A1 (en) * 2009-12-31 2013-08-01 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
CA2787331A1 (en) * 2010-01-25 2011-07-28 Hazel H. Szeto Aromatic-cationic peptides and uses of same
EP3167896A1 (en) * 2010-02-26 2017-05-17 University of Florida Research Foundation, Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP3560508A1 (en) * 2010-03-15 2019-10-30 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
US20110245183A1 (en) 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
US20110245182A1 (en) 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
EP2942354A1 (en) * 2010-05-03 2015-11-11 Stealth Peptides International, Inc. Aromatic-Cationic Peptides and Uses of Same
WO2014137496A1 (en) * 2013-03-08 2014-09-12 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
US20160176930A1 (en) 2010-07-09 2016-06-23 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
CN106620645A (zh) * 2010-07-09 2017-05-10 康德生物医疗技术公司 预防或治疗缺血/再灌注损伤之后无复流的方法
US20120083452A1 (en) 2010-09-30 2012-04-05 Perricone Nicholas V Topical Anesthetic Uses of Szeto-Schiller Peptides
CN107219358A (zh) * 2011-03-24 2017-09-29 康奈尔大学 芳香族阳离子肽及其用途
CA2849073A1 (en) * 2011-09-19 2013-03-28 Gencia Corporation Modified creatine compounds
CN106913860A (zh) * 2011-09-29 2017-07-04 梅约医学教育与研究基金会 芳族阳离子肽和使用它们的方法
EP2768516A4 (en) * 2011-10-17 2015-08-19 Univ Cornell AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
EP3656394A1 (en) * 2011-12-09 2020-05-27 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
DK2830644T3 (en) 2012-03-30 2017-02-27 Stealth Peptides Int Inc Methods and Preparations for the Prevention and Treatment of Neuropathy
EP3132800A1 (en) * 2012-08-02 2017-02-22 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis
KR20160009008A (ko) * 2012-10-22 2016-01-25 스텔스 바이오테라퓨틱스 코포레이션 심부전과 관련된 위험 및 이와 관련된 인자를 감소시키는 방법
CN115990242A (zh) 2013-03-01 2023-04-21 康德生物医疗有限公司 预防或治疗巴斯综合征的方法和组合物
US10793597B2 (en) * 2013-03-01 2020-10-06 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial diseases associated with a mutation in SURF 1 or POLG gene resulting in a disruption of mitochondrial oxidative phosphorylation
EP2989120A4 (en) 2013-04-25 2017-04-19 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof
WO2014209905A2 (en) 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods and compositions for detecting and diagnosing diseases and conditions
WO2015017781A1 (en) * 2013-08-01 2015-02-05 Stealth Peptides International, Inc. Methods and compositions for preventing or treating leber's hereditary optic neuropathy
CA2920020C (en) 2013-08-02 2023-03-14 Stealth Biotherapeutics Corp Methods and compositions for the prevention and treatment of friedreich's ataxia
CA2925757A1 (en) * 2013-09-30 2015-04-02 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity
EP3154694A1 (en) 2014-06-13 2017-04-19 Children's Medical Center Corporation Products and methods to isolate mitochondria
PL3160984T3 (pl) 2014-06-25 2021-10-25 Flamma S.P.A. Sposób wytwarzania d-arginylo-2,6-dimetylo-l-tyrozylo-l-lizylol- fenyloalaninoamidu
WO2016001042A1 (en) 2014-06-30 2016-01-07 Flamma S.P.A. Process for the production of d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
WO2016004093A2 (en) * 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
CN104306954B (zh) * 2014-09-25 2016-08-24 中山大学 Wry三肽在制备治疗阿尔茨海默症药物中的用途
US10603325B2 (en) 2014-10-29 2020-03-31 University Of Maryland Methods of treating age-related symptoms in mammals and compositions therefor
WO2017015660A1 (en) * 2015-07-23 2017-01-26 Salk Institute For Biological Studies Prevention and treatment of aging and neurodegenerative diseases
US20200308220A1 (en) * 2015-11-30 2020-10-01 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
CN115160402A (zh) * 2016-03-11 2022-10-11 隐形生物治疗公司 结晶盐形式
CN109563131A (zh) 2016-04-11 2019-04-02 卡诺有限责任公司 手性肽
WO2018100893A1 (ja) 2016-11-30 2018-06-07 株式会社ダイセル 撮像装置用レンズモジュール及びその製造方法
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
EP3668837B1 (en) 2017-08-17 2022-07-06 XWPharma Ltd. Preparation and uses of reactive oxygen species scavenger derivatives
ES2947741T3 (es) 2017-09-04 2023-08-17 Xwpharma Ltd Preparación y uso de un barredor de especies reactivas de oxígeno
JP6958860B2 (ja) * 2017-11-07 2021-11-02 学校法人自治医科大学 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
IL284006B1 (en) * 2018-12-18 2024-08-01 Stealth Biotherapeutics Corp Mitochondria-targeted peptides
WO2020222866A1 (en) * 2019-05-02 2020-11-05 Children's Medical Center Corporation Prophylactic and therapeutic use of mitochondria and combined mitochondrial agents
EP3771467A1 (en) 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 for the prevention and/or treatment of aneurysm
CN116390723A (zh) 2020-09-09 2023-07-04 社会利益网络公司 用于将生物素递送至线粒体的方法和组合物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5602100A (en) 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
DE68926269T2 (de) 1988-06-30 1996-08-14 Astra Ab Dermorphin-Analoge, deren Herstellungsverfahren, pharmazeutische Zusammensetzungen und Methode zur therapeutischen Behandlung unter Verwendung der Analoge
US5652122A (en) 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
ATE165208T1 (de) * 1990-01-17 1998-05-15 Univ California Zusammensetzung zur verbesserung der lebenserhaltung biologischer materialien
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
ATE255450T1 (de) * 1995-06-09 2003-12-15 Hisamitsu Pharmaceutical Co Matrix für iontophorese
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
CA2270661A1 (en) * 1996-10-07 1998-04-16 Lawrence Joseph Heinz Novel compounds useful as neuro-protective agents
US5885958A (en) 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
WO1999029721A1 (en) 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
CA2329709A1 (en) * 1998-04-24 1999-11-04 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
GB9905503D0 (en) * 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
WO2001025486A1 (en) * 1999-10-04 2001-04-12 University Of Medicine And Dentistry Of New Jersey Methods for identifying rna binding compounds
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
US7498297B2 (en) * 2000-07-18 2009-03-03 Cornell Research Foundation Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
JP2004523490A (ja) * 2000-11-28 2004-08-05 ギルフォード ファーマシュウティカルズ インコーポレイテッド 二置換カルボサイクリックサイクロフィリン結合化合物とその用途
US6545097B2 (en) * 2000-12-12 2003-04-08 Scimed Life Systems, Inc. Drug delivery compositions and medical devices containing block copolymer
WO2002059080A2 (en) * 2001-01-25 2002-08-01 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
US20030077826A1 (en) * 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
ATE434418T1 (de) * 2001-02-16 2009-07-15 Cordis Corp Verfahren zur herstellung eines ballonkatheter- stentapplikationssystems mit furchen
WO2002074194A2 (en) * 2001-03-16 2002-09-26 Sts Biopolymers, Inc. Stent with medicated multi-layer hydrid polymer coating
JPWO2002102833A1 (ja) * 2001-06-15 2004-09-30 千寿製薬株式会社 新規エンドモルフィン誘導体
CN101440124B (zh) * 2003-02-04 2012-07-18 科内尔研究基金会 用于防止线粒体通透性改变的方法
EP3659618A1 (en) * 2003-02-04 2020-06-03 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
PT2604285E (pt) 2003-05-01 2014-11-12 Cornell Res Foundation Inc Método e complexos transportadores para entregar moléculas às células
JP2005005762A (ja) * 2003-06-09 2005-01-06 Fujitsu Ltd 送信電力制御方法及び装置
US7232824B2 (en) 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
CA2971928C (en) 2004-01-23 2019-01-08 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
EP3725324A1 (en) 2005-09-16 2020-10-21 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing cd36 expression

Also Published As

Publication number Publication date
EP1599216B9 (en) 2015-02-11
ES2540897T3 (es) 2015-07-14
JP2017095519A (ja) 2017-06-01
HK1209652A1 (en) 2016-04-08
US20230293624A1 (en) 2023-09-21
EP2491943A3 (en) 2013-01-23
DK1599216T3 (da) 2013-12-09
US20120021970A1 (en) 2012-01-26
JP2006516652A (ja) 2006-07-06
JP2019089773A (ja) 2019-06-13
EP3305313A1 (en) 2018-04-11
US8957030B2 (en) 2015-02-17
JP2015180693A (ja) 2015-10-15
US20070027087A1 (en) 2007-02-01
US20200038472A1 (en) 2020-02-06
US7718620B2 (en) 2010-05-18
PT2656854E (pt) 2015-09-03
JP6126059B2 (ja) 2017-05-10
AU2004209663A1 (en) 2004-08-19
AU2004209663A2 (en) 2004-08-19
EP2656854A1 (en) 2013-10-30
SI2656854T1 (sl) 2015-09-30
JP5775285B2 (ja) 2015-09-09
WO2004070054A2 (en) 2004-08-19
CN104225574A (zh) 2014-12-24
WO2004070054A3 (en) 2005-04-14
CN104225574B (zh) 2017-01-11
EP3659618A1 (en) 2020-06-03
EP1599216A4 (en) 2009-11-11
EP3479838A1 (en) 2019-05-08
US20150359838A1 (en) 2015-12-17
HK1190930A1 (en) 2014-07-18
HK1178794A1 (en) 2013-09-19
US7576061B2 (en) 2009-08-18
HK1090571A1 (en) 2006-12-29
EP2865385B1 (en) 2016-11-16
EP1599216A2 (en) 2005-11-30
US20040248808A1 (en) 2004-12-09
EP1599216B1 (en) 2013-11-06
PT1599216E (pt) 2013-12-17
US8404646B2 (en) 2013-03-26
EP2865385A1 (en) 2015-04-29
CA2515080A1 (en) 2004-08-19
CA2515080C (en) 2012-04-10
DK2865385T3 (en) 2016-12-19
US20130244957A1 (en) 2013-09-19
US20100190718A1 (en) 2010-07-29
DK2656854T3 (en) 2015-07-06
JP4838114B2 (ja) 2011-12-14
HK1204999A1 (en) 2015-12-11
CN102784383A (zh) 2012-11-21
JP2013249313A (ja) 2013-12-12
JP6166312B2 (ja) 2017-07-19
CN102617706A (zh) 2012-08-01
CN102784383B (zh) 2014-09-17
JP5837542B2 (ja) 2015-12-24
EP2491943B1 (en) 2018-10-10
EP2656854B1 (en) 2015-05-20
ES2436011T3 (es) 2013-12-26
JP2011026346A (ja) 2011-02-10
JP2015007127A (ja) 2015-01-15
EP3842055A1 (en) 2021-06-30
HUE027110T2 (en) 2016-08-29
CY1114959T1 (el) 2016-12-14
EP2491943A2 (en) 2012-08-29
HK1131995A1 (en) 2010-02-12
EP3144009A1 (en) 2017-03-22
ES2605504T3 (es) 2017-03-14
AU2004209663B2 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
CY1116575T1 (el) Χρησεις αρωματικου-κατιοντικου πεπτιδιου
CY1115305T1 (el) Μεθοδοι για την προληψη ή τη θεραπεια της αντιστασης στην ινσουλινη
CY1109439T1 (el) Αναλογα γλυκοπρωτεϊνικων ορμονων δισουλφιδικης σταυρωτης συνδεσης, η παρασκευη και η χρηση τους
CY1110177T1 (el) Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης
CY1115885T1 (el) Αντιστρεπτα πεγκυλιωμενα (pegylated) φαρμακα
CY1115580T1 (el) Συνθεση και αντι-ιικη δραστηριοτητα των υποκατεστημενων παραγωγων αζαϊνδολοοξικης πιπεραζινης
DE60325968D1 (de) Prodrugs von exzitatorischen aminosäuren
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
CY1112330T1 (el) Πρωτεϊνες συνδεσης gag
BR0205491B1 (pt) compressor com elemento espiralado e com injeção de vapor.
WO2007035640A3 (en) Methods for reducing cd36 expression
BR0209434A (pt) Peptìdeos antimicrobianos e composições
CY1108570T1 (el) Gd3-μιμητικα πεπτιδια
RU2009147217A (ru) Новые противоопухолевые соединения
ES2171923T3 (es) Profarmacos de la talidomida, su procedimiento de preparacion y su utilizacion como principios activos en medicamentos.
ATE278710T1 (de) Antimikrobiell wirksame peptide
CY1112236T1 (el) Πεπτιδια που ειναι σε θεση να αναστελλουν την αλληλεπιδραση μεταξυ των πρεσενιλινων και του βητα-αμυλοειδους πεπτιδιου ή του προδρομου
EA200000950A1 (ru) Ингерентно свето- и термостабилизированные полиамиды с улучшенной устойчивостью к мокрым обработкам
ATE495247T1 (de) Chromoprotein und fluoroproteine
ITRM940134A1 (it) Circuito per combinare insieme gruppi di sequenze di cifre per formare codici di identificazione telefonici e relativo procedimento
DE69800172D1 (de) Mit Organohydrogensiloxan-Vernetzen härtbare Organosiloxan-Zusammensetzunt mit verbesserten Hysterese-Eigenschaften
DE69532302D1 (de) Peptide gegen pilzen
DE60304067D1 (de) Kraftstoffeinspritzsystem
KR910018404A (ko) 혈소판-응집 억제제
NO20051840L (no) IHNV G-protein til immunstimulering.